Cargando…
Modified quadruple therapy versus bismuth-containing quadruple therapy in first-line treatment of Helicobacter pylori infection in Korea; rationale and design of an open-label, multicenter, randomized controlled trial
BACKGROUND: Clarithromycin-containing triple regimen for eradication of Helicobacter pylori is no longer acceptable in Korea due to high clarithromycin resistance. Concomitant therapy or bismuth-containing quadruple therapy is recommended as an alternative regimen. A recent study in Korea has shown...
Autores principales: | Lim, Hyun, Bang, Chang Seok, Shin, Woon Geon, Choi, Jae Ho, Soh, Jae Seung, Kang, Ho Suk, Yang, Young Joo, Hong, Ji Taek, Shin, Suk Pyo, Suk, Ki Tae, Lee, Jae Jun, Baik, Gwang Ho, Kim, Dong Joon |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6257664/ https://www.ncbi.nlm.nih.gov/pubmed/30431605 http://dx.doi.org/10.1097/MD.0000000000013245 |
Ejemplares similares
-
Comparison of the Eradication Rate between 1- and 2-Week Bismuth-Containing Quadruple Rescue Therapies for Helicobacter pylori Eradication
por: Yoon, Jai Hoon, et al.
Publicado: (2012) -
Bismuth-Based Quadruple Therapy versus Metronidazole-Intensified Triple Therapy as a First-Line Treatment for Clarithromycin-Resistant Helicobacter pylori Infection: A Multicenter Randomized Controlled Trial
por: Seo, Seung In, et al.
Publicado: (2022) -
Second-line bismuth-containing quadruple therapy for Helicobacter pylori eradication and impact of diabetes
por: Kim, Sung Eun, et al.
Publicado: (2017) -
Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori
por: Gisbert, Javier P, et al.
Publicado: (2012) -
Susceptibility-guided bismuth quadruple therapies for resistant Helicobacter pylori infections
por: Yang, Tiankuo, et al.
Publicado: (2020)